U.S. Software Stock News

NYSE:UI
NYSE:UICommunications

Is It Too Late To Consider Ubiquiti (UI) After A 36% One-Year Rally?

If you are wondering whether Ubiquiti’s recent share price puts it at an attractive entry point or a stretched one, this article walks through the key valuation angles you should be thinking about. The stock last closed at US$553.52, with returns of 0.8% over 7 days, a 0.9% decline over 30 days, a 2.3% decline year to date, and a 35.6% gain over 1 year, alongside gains of 104.0% over 3 years and 122.0% over 5 years. Recent price moves are best viewed against ongoing investor interest in...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is Dentsply Sirona (XRAY) Pricing Reflect Recent Slide In Dental Equipment Sentiment Accurately

If you are wondering whether DENTSPLY SIRONA’s share price reflects its underlying worth, you are not alone. This article walks through what the current market price might be implying about value. The stock closed at US$12.58, with returns of 0.8% over the past week and 10.6% over the past month, set against a year to date return of 11.6% and a 1 year return of a 28.4% decline. Recent coverage has focused on how investors are reassessing dental and medical equipment names like DENTSPLY...
NasdaqGS:ORIC
NasdaqGS:ORICBiotechs

Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration

ORIC Pharmaceuticals (ORIC) stock has been in focus after fresh buy ratings from several research firms coincided with encouraging trial updates for its lead oncology drugs and a new collaboration with Johnson & Johnson. See our latest analysis for ORIC Pharmaceuticals. The recent news flow and analyst enthusiasm appear to be feeding into the share price, with ORIC’s 7 day share price return of 36.33% and year to date share price return of 41.00% standing against a 1 year total shareholder...
NYSE:KNF
NYSE:KNFBasic Materials

Assessing Knife River (KNF) Valuation After Wells Fargo Downgrade And Higher Price Target

Wells Fargo downgrade puts Knife River in focus Wells Fargo’s decision to downgrade Knife River (KNF) to Equal-Weight while lifting its price target to $81 has put fresh attention on the stock and how analysts currently view its prospects. See our latest analysis for Knife River. Knife River’s recent momentum has been firm, with a 23.6% 90 day share price return and year to date share price return of 10.31% taking the stock to $80.24, even though the 1 year total shareholder return is a...
NYSE:GIC
NYSE:GICTrade Distributors

How Investors May Respond To Global Industrial (GIC) Earnings Miss And Slowing Revenue Amid Supply Chain Strains

In its recent quarterly update, Global Industrial reported year-on-year revenue growth of 3.3% but missed analyst expectations on sales, EBITDA, and EPS, marking the slowest revenue growth and weakest performance versus estimates among maintenance and repair distributors. The results also underscored ongoing supply chain and inventory management difficulties, emphasizing how operational execution remains a central issue for the company and its peers. Next, we will examine how Global...
NYSE:IIIN
NYSE:IIINBuilding

Insteel Industries (IIIN) Net Margin Rebound Challenges Bearish Earnings Narratives

Insteel Industries (IIIN) opened its new fiscal year with Q1 2026 revenue of US$159.9 million and basic EPS of US$0.39, alongside net income of US$7.6 million. The company has seen revenue move from US$129.7 million and EPS of US$0.06 in Q1 2025 to a trailing twelve month revenue base of US$677.9 million and EPS of US$2.44. This gives investors a clearer sense of the earnings power behind the latest quarter and the improvement in net margin from 3.6% to 7% over the past year. See our full...
NYSE:J
NYSE:JProfessional Services

Is Jacobs Solutions (J) Fairly Priced After Recent Steady Multi Year Share Gains

Wondering if Jacobs Solutions at around US$141.50 is giving you fair value for the risk you take, or if the price is leaving too much on the table. The stock has seen returns of 2.2% over the last 7 days, 5.6% over 30 days, 4.5% year to date, 4.3% over 1 year, 48.1% over 3 years and 60.4% over 5 years, which naturally raises questions about how much of that performance is already reflected in the current share price. Recent news around Jacobs Solutions has focused on its role as a large US...
NasdaqGS:GLNG
NasdaqGS:GLNGOil and Gas

The Bull Case For Golar LNG (GLNG) Could Change Following Long-Term Argentina FLNG Charter Progress - Learn Why

In the past few months, Goldman Sachs began covering Golar LNG Limited with a positive view, while Golar confirmed that all Conditions Precedent for its 20‑year MKII FLNG charter with Southern Energy in Argentina had been satisfied, securing a long-term commercial arrangement. These developments, occurring against the backdrop of Argentina’s recent election of Javier Milei, meaningfully reduce policy uncertainty around the project and sharpen focus on Golar’s exposure to LNG-linked commodity...
NasdaqGS:BBSI
NasdaqGS:BBSIProfessional Services

Assessing Barrett Business Services (BBSI) Valuation After New Employee File Cabinet HR Tech Launch

What the new Employee File Cabinet launch means for BBSI shareholders Barrett Business Services (BBSI) has rolled out its Employee File Cabinet HRIS module within the BBSI Client Portal, built with Box, giving clients a secure, centralized hub for key HR documents. The launch highlights BBSI’s ongoing push to consolidate HR workflows into a single portal experience. The company points to potential benefits around compliance, time savings, and employee access to their own documents. See our...
NYSE:NRGV
NYSE:NRGVElectrical

Why Energy Vault (NRGV) Is Up 11.5% After Launching Its First ERCOT Asset Vault Project

Energy Vault Holdings, Inc. previously filed a shelf registration for US$180.55 million of common stock, while also beginning construction on the 150 MW/300 MWh SOSA Energy Center battery storage project in Madison County, Texas under its Asset Vault "Own & Operate" platform. This combination of fresh financing capacity and the company’s first Asset Vault project in the ERCOT North market highlights a shift toward owned infrastructure backed by recurring revenues and supported by a US$300...
NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

Is Illumina (ILMN) Pricing Reflect Its Worth After Regulatory Scrutiny And Mixed Long Term Returns

If you are wondering whether Illumina's current share price reflects its true worth, this article walks through the key numbers that matter before you make up your mind. Illumina's stock recently closed at US$145.30, with returns of 10.4% over 30 days, 8.2% year to date and 5.8% over 1 year, but declines of 23.9% over 3 years and 63.1% over 5 years, highlighting how mixed the journey has been for long term holders. Recent news around Illumina has focused on ongoing questions about its...
NasdaqGS:CVGW
NasdaqGS:CVGWFood

Calavo Growers (CVGW) Margin Turnaround Challenges Cautious Earnings Narratives

Calavo Growers (CVGW) just wrapped up FY 2025 with Q4 revenue of US$124.7 million and basic EPS of US$0.21. Trailing 12 month revenue came in at US$648.4 million and EPS at US$1.11, supported by a trailing net profit margin of 3.1% versus 1.0% in the prior year. Over the last few quarters, revenue has ranged from US$154.4 million to US$190.5 million with quarterly EPS between US$0.21 and US$0.38. This points to a picture of improving profitability that puts margins, rather than top line...
NYSE:MS
NYSE:MSCapital Markets

Morgan Stanley (MS) Earnings Surge And Margin Strength Challenge Cautious Growth Narratives

Morgan Stanley (MS) has wrapped up FY 2025 with fourth quarter revenue of US$17.9b and basic EPS of US$2.72, capping a twelve month run that produced total revenue of US$70.3b and basic EPS of US$10.32, alongside a 26.9% rise in earnings and a net profit margin of 23.1% compared with 20.8% the year before. Over the past six quarters, the bank has seen quarterly revenue move from US$15.3b in Q3 2024 to US$17.9b in Q4 2025, while quarterly basic EPS moved from US$1.91 to US$2.72. This set up a...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Assessing Axsome Therapeutics (AXSM) After An 86% One-Year Share Price Surge

Wondering if Axsome Therapeutics at around US$174 a share still offers value, or if most of the opportunity has already been priced in? This article is built to help you frame that question clearly. The stock has seen a 3.9% return over the past week and 18.6% over the last 30 days, while year to date it is at a 2.5% decline and up 85.9% over the last year and 155.9% over three years, with a 129.4% return over five years. Recent coverage of Axsome has focused on its position in...
NYSE:DEI
NYSE:DEIOffice REITs

Is Douglas Emmett (DEI) Now Attractive After Prolonged Share Price Weakness And Office Market Concerns

If you are wondering whether Douglas Emmett is priced attractively today, or if the share price still does not reflect its underlying real estate assets, this article explains what the current market value might be telling you. The stock recently closed at US$10.97, with returns of a 1.6% decline over 7 days, a 4.8% decline over 30 days, a 0.9% decline year to date, a 32.8% decline over 1 year and a 51.5% decline over 5 years. This performance may have changed how investors view its risk and...
NasdaqCM:SLS
NasdaqCM:SLSBiotechs

A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Collaboration

SELLAS Life Sciences Group (SLS) is back on investor radars after it agreed with the IMPACT AML network to run a European clinical study of its CDK9 inhibitor, SLS009, in high risk newly diagnosed AML. See our latest analysis for SELLAS Life Sciences Group. The new IMPACT AML agreement comes after a volatile spell where traders focused on financing risk, yet the stock still shows a 74.55% 30 day share price return and a very large 1 year total shareholder return. This suggests momentum has...
NYSE:GENI
NYSE:GENIHospitality

Should Wall Street’s Praise of GENI’s Media Strategy Refocus the Genius Sports (GENI) Investment Debate?

In recent days, multiple research firms including Benchmark, Wells Fargo, and Truist Financial have issued upbeat coverage on Genius Sports, emphasizing its operating leverage, media monetization approach, and long-term revenue and cash flow ambitions. This wave of positive attention underscores how Genius Sports’ data partnerships and advertising-focused media strategy have become central to its long-term business case. Building on this new analyst optimism around Genius Sports’ media...
NYSE:GS
NYSE:GSCapital Markets

Goldman Sachs Group (GS) Earnings Rebound And 27.4% Margin Test Moderate Growth Narratives

Goldman Sachs FY 2025 Earnings Snapshot Goldman Sachs (GS) closed out FY 2025 with fourth quarter revenue of US$15.6 billion and basic EPS of US$14.27 on net income of US$4.4 billion, setting the tone for how investors are reading the latest numbers. Over the past six reported quarters, the bank has seen quarterly revenue move from US$12.3 billion in Q3 2024 to US$13.5 billion in Q4 2024 and then to US$15.6 billion in Q4 2025, while basic EPS shifted from US$8.52 to US$12.14 to US$14.27 over...
NYSE:OSK
NYSE:OSKMachinery

Is Oshkosh (OSK) Still Attractive After A 63% One Year Share Price Surge

If you are wondering whether Oshkosh is actually good value at its current share price, this article walks through the key numbers so you can judge that for yourself. The stock last closed at US$150.77, with returns of 6.4% over 7 days, 16.0% over 30 days, 14.0% year to date, 63.2% over 1 year, 70.4% over 3 years and 71.0% over 5 years, which puts recent valuation questions front and center. Recent headlines around Oshkosh have focused on its position in the capital goods space and investor...
NasdaqCM:MREO
NasdaqCM:MREOBiotechs

Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift

Mereo BioPharma Group recently reported that its Phase 3 Orbit and Cosmic trials of setrusumab in osteogenesis imperfecta missed their primary fracture reduction endpoints but achieved strong statistical improvements in bone mineral density, while also updating investors that its approximately US$41,000,000 cash balance at 31 December 2025 is expected to fund operations to mid-2027. Alongside reassessing the future of setrusumab with partner Ultragenyx, Mereo is pushing ahead with a single...
NYSE:ALV
NYSE:ALVAuto Components

Is Autoliv (ALV) Attractive After Strong Multi Year Share Price Performance

If you are wondering whether Autoliv’s current share price lines up with its underlying value, this breakdown is designed to walk you through the key numbers that matter. Autoliv shares last closed at US$128.45, with returns of 4.2% over 7 days, 5.9% over 30 days, 5.2% year to date, 36.0% over 1 year and 71.8% over 3 years. This naturally raises questions about how much of this performance is already reflected in the price. Recent attention on Autoliv has centered on its position in vehicle...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

Is It Time To Reassess Fiserv (FISV) After A Steep Multi Year Share Price Slump

If you are wondering whether Fiserv's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. Fiserv shares last closed at US$67.50, with returns of a 1.8% decline over 7 days, a 2.1% decline over 30 days, a 2.9% gain year to date, and declines of 67.0% over 1 year, 34.6% over 3 years and 38.2% over 5 years. Recent headlines around Fiserv have focused on its role as a major provider of payments and financial...
NYSE:GAM
NYSE:GAMCapital Markets

Does GAM’s Preferred Buybacks and Insider Buying Reveal a Deeper Capital Allocation Play?

General American Investors Company recently renewed its preferred stock repurchase program, authorizing buybacks of up to 1,601,553 preferred shares when they trade below the US$25 liquidation preference, and Vice President Eugene Stark purchased 4,000 preferred shares for US$99,920. Together, the renewed buyback capacity and insider purchase highlight how the firm is actively managing its capital structure while signaling internal commitment to the preferred stock. Next, we will examine how...
NasdaqCM:BLFS
NasdaqCM:BLFSLife Sciences

Stronger Q4 Revenue and Leadership Change Might Change The Case For Investing In BioLife Solutions (BLFS)

On January 8, 2026, BioLife Solutions, Inc. reported preliminary fourth-quarter and full-year 2025 unaudited revenue from continuing operations, indicating a 20% increase in fourth-quarter revenue that surpassed the high end of its previously raised 2025 revenue guidance, and also disclosed that Chief Quality and Operations Officer Karen Foster had earlier notified the company of her decision to retire effective March 31, 2026. This combination of stronger-than-expected revenue performance...